DDInter856 DDInter215
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth subsalicylate has been around for over 100 years: it was originally developed in 1901 for hygienic use and sanitation for cholera infection.[A230728, A230773] Bismuth subsalicylate was first approved by the FDA in 1939 and is now mainly used to relieve nausea, diarrhea, and gastrointestinal discomfort. It is an active ingredient found in Pepto-Bismol, a common over-the-counter medication that is used to temporarily treat discomforts of the stomach and gastrointestinal tract. Bismuth subsalicylate is a component of HELIDAC Therapy (bismuth subsalicylate, [metronidazole], and [tetracycline]), which is a treatment regimen indicated for the eradication of _H. pylori_ for treatment of patients with _H. pylori_ infection and duodenal ulcer disease.
Bismuth subsalicylate {u} (Compound) binds {v} (Gene) TF
Bismuth subsalicylate {u} (Compound) is included by {v} (Pharmacologic Class) Bismuth
Bismuth subsalicylate {u} (Compound) causes {v} (Side Effect) Infection
Bismuth subsalicylate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clopidogrel
Bismuth subsalicylate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desirudin
Bismuth subsalicylate {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Bismuth subsalicylate {u} may lead to a major life threatening interaction when taken with {v} Methotrexate
Bismuth subsalicylate (Compound) binds TF (Gene)
Bismuth subsalicylate (Compound) is included by Bismuth (Pharmacologic Class)
Bismuth subsalicylate (Compound) causes Infection (Side Effect)
Bismuth subsalicylate may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Bismuth subsalicylate may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Bismuth subsalicylate may lead to a major life threatening interaction when taken with Ramucirumab
Bismuth subsalicylate may lead to a major life threatening interaction when taken with Methotrexate